Takeda Fails In Effort To Get U.K. Coverage For Pulmonary-Disease Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical failed to win the U.K.’s National Institute for Health and Clinical Excellence support for Daxas (roflumilast) for severe COPD.